You just read:

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer

News provided by

Syndax Pharmaceuticals

Sep 24, 2018, 16:05 ET